Previous close | 0.5500 |
Open | 0.5800 |
Bid | 0.0000 |
Ask | 0.0500 |
Strike | 11.00 |
Expiry date | 2024-05-17 |
Day's range | 0.5500 - 0.5800 |
Contract range | N/A |
Volume | |
Open interest | 59 |
NASHVILLE, Tenn., May 15, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:
NASHVILLE, Tenn., May 13, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for t
NASHVILLE, Tenn., May 13, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow’s commitment to enhancing its leadership structure to support the Company’s continued growth. John Saharek,